TP53 and lung cancer: Therefore, both the genetic manipulation of Akt1 in the SPC-IGFIR transgenic mice and the use of a selective AKT1 inhibitor in human lung cancer cell lines suggests that AKT1 is a critical regulator of lung adenocarcinoma development, particularly in tumor cells containing wild type p53. Currently only the MK-2206 is being evaluated in clinical trials and our data suggests that AKT1 selective inhibitors may warrant evaluation in clinical trials, at least for lung adenocarcinomas expressing wild type p53.